Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Globe Newswire•26/10/2026•08:30 ET
0
Key Highlights
- ➤First subject dosed in EQ504 Phase 1 trial; topline data expected Q2 2027
- ➤Equillium expects $20 million milestone financing to close, totaling approximately $50 million
- ➤$20 million proceeds expected to fund currently planned operations into 2029
- ➤Proof-of-concept ulcerative colitis study anticipated in second half of 2027, pending supportive data
Expert Statements
Bruce Steel, Chief Executive Officer of Equillium
“Dosing the first participant in our Phase 1 trial marks an important milestone as we advance EQ504, our differentiated, oral, colon-targeted AhR modulator, into clinical development.”
Bruce Steel, Chief Executive Officer of Equillium
“We believe EQ504's locally acting and non-immunosuppressive approach has the potential to address important unmet medical needs in ulcerative colitis and other serious inflammatory diseases.”
Bruce Steel, Chief Executive Officer of Equillium
“The Phase 1 trial is designed to evaluate safety and tolerability, as well as characterize EQ504’s pharmacokinetic and pharmacodynamic profile to assess proof of mechanism.”
Bruce Steel, Chief Executive Officer of Equillium
“Subject to supportive topline Phase 1 data, expected in Q2 2027, we anticipate initiating a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.”
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027
Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504
Get started
Create a free account to read the full story.